ClinicalTrials.gg
CompletedNCT01842581Updated Sep 9, 2019Results posted

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

A Phase 4 interventional study of Rifaximin and Lactulose in Hepatic Encephalopathy and Cirrhosis, sponsored by Bausch Health Americas, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2013, registered Apr 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.

Enrollment
5th of 18
222 · median 94
Started
2013
with 3 others
Phase 4
8 of 18
2 open now
Registered
9th of 18
by date
Lead sponsor
4 of 18
Bausch Health Americas, Inc.

Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 5th largest by enrollment, is one of 4 that started in 2013, is one of 8 in phase 4, and was the 9th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rifaximin in Hepatic Encephalopathy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.

03

Conditions studied

  • Hepatic Encephalopathy
  • Cirrhosis

Keywords

  • Liver Failure
  • Hepatic Insufficiency
  • Liver Diseases
  • Brain Diseases
  • Rifaximin
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating females greater than or equal to (≥) 18 years old.
  • In remission from demonstrated overt HE (Conn score 0 or 1).
  • Have had one or more episodes of overt HE associated with cirrhosis within 6 months prior to screening visit (Day -7 to -1).
  • Participant has a close family member or other personal contact who is familiar with the participant's HE and can provide continuing oversight to the participant and is willing to perform as caregiver for the participant during the conduct of the trial.

Exclusion criteria

Exclusion Criteria:

  • Participant has been diagnosed with (HIV) as determined by medical history.
  • History of tuberculosis infection.
  • Participant has been diagnosed with chronic respiratory insufficiency.
  • Participant has been diagnosed with a current infection for which they are currently taking oral or parenteral antibiotics.
  • Renal insufficiency requiring routine dialysis.
  • Participant has an active spontaneous bacterial peritonitis(SBP) infection.
  • Intestinal obstruction or inflammatory bowel disease.
  • Participant has active within the last 5 years prior to screening visit, except basal cell carcinoma of the skin, or if female, in situ cervical carcinoma that has been surgically excised.
  • Current gastrointestinal (GI) bleeding or has a history of a GI hemorrhage of sufficient severity to require hospitalization and a transfusion of ≥2 units of blood within 3 months prior to screening visit.
  • Participant is anemic, as defined by a of less than (\<) 8 grams/deciliter (g/dL).
  • Scheduled to receive a liver transplant within 1 month of screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Rifaximin 550 mg BID

    Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.

    Drug: Rifaximin

  • Experimental
    Rifaximin 550 mg BID + Lactulose

    Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.

    Drug: Rifaximin · Drug: Lactulose

Interventions

  • Rifaximin will be administered per the dose and schedule specified in the arms.

    Also known as: Xifaxan®

  • Laculose will be administered per the schedule specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting a First Breakthrough HE Episode

    A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented.

    Time frame: From randomization (Day 1) up to Day 170

Secondary outcomes

  1. Number of Participants Who Were Hospitalized Due to HE Episode

    An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented.

    Time frame: From randomization (Day 1) up to Day 170

  2. Number of Participants Who Died Due to Any Reason

    Time frame: From randomization (Day 1) up to end of study (Day 186)

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that occurred from first dose of study drug until last dose of study drug plus 5 days (for non-fatal AEs) or plus 30 days (for fatal AEs).A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: From randomization (Day 1) up to end of study (Day 186)

  2. Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170

    CLDQ was used to measure health-related quality of life. CLDQ includes 29 items in the following 6 domains: abdominal symptoms (3 items), fatigue (5 items), systemic symptoms (5 items), activity (3 items), emotional function (8 items), and worry (5 items). All items were measured on a 7-point Likert scale, ranging from 0 to 6 with higher values indicating better quality of life. Each domain score of CLDQ was calculated as the mean of the responses of items in that domain. Overall CLDQ score was obtained by adding scores for each item and dividing by the total number of items. Overall CLDQ score ranged from 0 (most impairment) to 6 (least impairment) with higher scores indicating better quality of life. If at least half of the items were non-missing for a domain, mean values of the non-missing items for that domain were used as imputed values for missing values. If more than half of the items in a domain were missing, no values were imputed and domain score was considered as missing.

    Time frame: Baseline, Day 170

  3. Change From Baseline in Critical Flicker Frequency (CFF) at Day 170

    The critical flicker frequency (CFF), a validated assessment of neurological function was assessed using a specialized CFF instrument. The CFF is the frequency at which the participant observes a constant light transition to a flickering light and was measured in Hertz. The CFF was measured on a continuous scale and was the mean of 8 separate fusion-to-flicker transition tests performed in rapid succession. Increases in CFF results represent improvement in neurological function in participants with HE.

    Time frame: Baseline, Day 170

07

Results

Posted Sep 9, 2019
Limitations and caveats
The rifaximin monotherapy arm included a subset of rifaximin/lactulose dependent participants for whom lactulose was withdrawn upon randomization (88.5% of participants in that group), which led to earlier HE breakthrough in this subset.

Participant flow

Participant flow — Overall Study
MilestoneRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Started113109
Received at least 1 dose of study drug113108
Completed6979
Not completed4430
Withdrew: Adverse event64
Withdrew: He breakthrough2613
Withdrew: Liver transplant20
Withdrew: Lost to follow-up25
Withdrew: Withdrawal by subject57
Withdrew: Other than specified31

Outcome measures

PrimaryNumber of Participants Reporting a First Breakthrough HE Episode

A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented.

Time frame:
From randomization (Day 1) up to Day 170
Reported as:
Count of participants · Participants
Number of Participants Reporting a First Breakthrough HE Episode
ParticipantsRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Number of Participants Reporting a First Breakthrough HE Episode2815
Statistical analysis
  • Rifaximin 550 mg BID vs Rifaximin 550 mg BID + Lactulose · Score statistics · p = 0.0359 · Hazard ratio (hr): 1.959 · 95% CI 1.045 to 3.672
SecondaryNumber of Participants Who Were Hospitalized Due to HE Episode

An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented.

Time frame:
From randomization (Day 1) up to Day 170
Reported as:
Count of participants · Participants
Number of Participants Who Were Hospitalized Due to HE Episode
ParticipantsRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Number of Participants Who Were Hospitalized Due to HE Episode2314
Statistical analysis
  • Rifaximin 550 mg BID vs Rifaximin 550 mg BID + Lactulose · Log Rank · p = 0.0985 (Threshold for significance at 0.05 level.) · Hazard ratio (hr): 1.739 · 95% CI 0.894 to 3.382
SecondaryNumber of Participants Who Died Due to Any Reason
Time frame:
From randomization (Day 1) up to end of study (Day 186)
Reported as:
Count of participants · Participants
Number of Participants Who Died Due to Any Reason
ParticipantsRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Number of Participants Who Died Due to Any Reason22
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that occurred from first dose of study drug until last dose of study drug plus 5 days (for non-fatal AEs) or plus 30 days (for fatal AEs).A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
From randomization (Day 1) up to end of study (Day 186)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)9981
Other pre-specifiedChange From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170

CLDQ was used to measure health-related quality of life. CLDQ includes 29 items in the following 6 domains: abdominal symptoms (3 items), fatigue (5 items), systemic symptoms (5 items), activity (3 items), emotional function (8 items), and worry (5 items). All items were measured on a 7-point Likert scale, ranging from 0 to 6 with higher values indicating better quality of life. Each domain score of CLDQ was calculated as the mean of the responses of items in that domain. Overall CLDQ score was obtained by adding scores for each item and dividing by the total number of items. Overall CLDQ score ranged from 0 (most impairment) to 6 (least impairment) with higher scores indicating better quality of life. If at least half of the items were non-missing for a domain, mean values of the non-missing items for that domain were used as imputed values for missing values. If more than half of the items in a domain were missing, no values were imputed and domain score was considered as missing.

Time frame:
Baseline, Day 170
Reported as:
Mean · units on a scale
Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170
units on a scaleRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Baseline4.13 ± 1.1104.26 ± 1.197
Change at Day 1700.29 ± 0.8600.08 ± 1.055
Other pre-specifiedChange From Baseline in Critical Flicker Frequency (CFF) at Day 170

The critical flicker frequency (CFF), a validated assessment of neurological function was assessed using a specialized CFF instrument. The CFF is the frequency at which the participant observes a constant light transition to a flickering light and was measured in Hertz. The CFF was measured on a continuous scale and was the mean of 8 separate fusion-to-flicker transition tests performed in rapid succession. Increases in CFF results represent improvement in neurological function in participants with HE.

Time frame:
Baseline, Day 170
Reported as:
Mean · hertz
Change From Baseline in Critical Flicker Frequency (CFF) at Day 170
hertzRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Baseline35.14 ± 7.76734.64 ± 7.290
Change at Day 1701.09 ± 7.2662.10 ± 6.699

Adverse events

Collected over From randomization (Day 1) up to end of study (Day 186). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin 550 mg BID—43/113 (38.1%)68/113 (60.2%)
Rifaximin 550 mg BID + Lactulose—35/108 (32.4%)53/108 (49.1%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Hepatic encephalopathyNervous system disorders21/11310/108
AscitesGastrointestinal disorders2/1137/108
Renal failure acuteRenal and urinary disorders6/1133/108
AnaemiaBlood and lymphatic system disorders5/1131/108
Urinary tract infectionInfections and infestations1/1134/108
CellulitisInfections and infestations3/1131/108
Supraventricular tachycardiaCardiac disorders0/1132/108
Gastrointestinal haemorrhageGastrointestinal disorders1/1132/108
Peritonitis bacterialInfections and infestations2/1132/108
PneumoniaInfections and infestations1/1132/108
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRifaximin 550 mg BIDRifaximin 550 mg BID + Lactulose
Oedema peripheralGeneral disorders19/11315/108
ConstipationGastrointestinal disorders18/1139/108
NauseaGastrointestinal disorders16/11311/108
FatigueGeneral disorders16/1139/108
InsomniaPsychiatric disorders13/11315/108
DiarrhoeaGastrointestinal disorders5/11313/108
Urinary tract infectionInfections and infestations12/1135/108
Muscle spasmsMusculoskeletal and connective tissue disorders9/11311/108
Pruritus generalisedSkin and subcutaneous tissue disorders11/1136/108
AscitesGastrointestinal disorders7/11310/108

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Rifaximin 550 mg BIDRifaximin 550 mg BID + LactuloseTotal
Mean58.1 ± 9.5158.8 ± 9.4958.4 ± 9.49
Sex: Female, Male
Sex: Female, Male(Participants)Rifaximin 550 mg BIDRifaximin 550 mg BID + LactuloseTotal
Female443882
Male6970139
Lactulose Usage Prior to First Dose
Lactulose Usage Prior to First Dose(Participants)Rifaximin 550 mg BIDRifaximin 550 mg BID + LactuloseTotal
Yes100100200
No13821
08

Study locations

43 sites
  • Banner Research
    Phoenix, Arizona 85016, United States
  • Southern California Liver Centers
    Coronado, California 92118, United States
  • UCSF/Fresno - CRMC
    Fresno, California 93721, United States
  • UCSD Clinical & Translational Research Institute
    La Jolla, California 92037, United States
  • Salix Site
    Long Beach, California 90822, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • Salix Site
    Riverside, California 92501, United States
  • Salix Site
    San Diego, California 92103, United States
  • Salix Site
    San Francisco, California 94115, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • South Denver GI
    Englewood, Colorado 80113, United States
  • University of Florida Hepatology
    Gainesville, Florida 32610-0277, United States
  • Tampa General Medical Group
    Tampa, Florida 33605, United States
  • Gastroenterology Associates
    Macon, Georgia 31201, United States
  • Salix Site
    Chicago, Illinois 60611, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Central Iowa Hospital Corp
    Des Moines, Iowa 50309-1453, United States
  • Salix Site
    Jefferson, Louisiana 70124, United States
  • Delta Research Partners, LLC
    Monroe, Louisiana 71201, United States
  • The Center for Liver and Biliary Disease
    Baltimore, Maryland 21202-2165, United States
  • Brigham and Women's Hospital Division of Gastroenterology & Hepatology
    Boston, Massachusetts 02115, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • St. Louis University
    Saint Louis, Missouri 63104, United States
  • Univ. of Nebraska Medical Center
    Omaha, Nebraska 68198-3285, United States
  • Concorde Medical Group PLLC
    New York, New York 10016, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • Salix Site
    New York, New York 10016, United States
  • Columbia University Medical Ctr. Center for Liver Disease & Transplantation
    New York, New York 10032, United States
  • University of Rochester Strong Memorial Hospital
    Rochester, New York 14642, United States
  • Asheville Gastroenterology Associates, PA
    Asheville, North Carolina 28801, United States
  • UNC School of Medicine/Division of Gastroenterology and Hepatology
    Chapel Hill, North Carolina 27599-7584, United States
  • Carolina Medical Center
    Charlotte, North Carolina 28204, United States
  • Integris Nazh Zuhdi Transplant Institute
    Oklahoma City, Oklahoma 73112, United States
  • Albert Einstien Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Research Specialists of Texas
    Houston, Texas 77030, United States
  • Amcare Research Inc
    Houston, Texas 77090, United States
  • Salix Site
    Odessa, Texas 79761, United States
  • Alamo Medical Research
    San Antonio, Texas 78215, United States
  • Methodist Hospital
    San Antonio, Texas 78229, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • VCU/MCV Health Systems
    Richmond, Virginia 23298, United States
  • University of Wisconsin Hospital & Clinics
    Madison, Wisconsin 53792, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Dec 2014, 23 months.

Results were first posted in Sep 2019, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2013
First posted
Apr 29, 2013
StartActual
Jan 8, 2013
Primary completionActual
Dec 17, 2014
CompletionActual
Dec 17, 2014
Results first posted
Sep 9, 2019
Last update
Sep 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01842581
Responsible party
Sponsor
First posted
Apr 29, 2013
Start date
Jan 8, 2013
Primary completion
Dec 17, 2014
Completion
Dec 17, 2014
Results posted
Sep 9, 2019
Last update
Sep 9, 2019

Study contacts

Lindsey Mathew
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion